BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng J, Wang W, Zhang Y, Liu X, Li M, Wu Z, Liu Z, Lv Y, Wang B. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS One. 2014;9:e87011. [PMID: 24498011 DOI: 10.1371/journal.pone.0087011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Elsayed MM, Mostafa ME, Alaaeldin E, Sarhan HA, Shaykoon MS, Allam S, Ahmed AR, Elsadek BE. Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma. Int J Nanomedicine 2019;14:8445-67. [PMID: 31754301 DOI: 10.2147/IJN.S223920] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
2 Wang ZF, Hu R, Pang JM, Zhang GZ, Yan W, Li ZN. Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett. 2018;16:1593-1601. [PMID: 30008842 DOI: 10.3892/ol.2018.8825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data. J Clin Lab Anal 2021;35:e23932. [PMID: 34403527 DOI: 10.1002/jcla.23932] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Sugiyama H, Takeshita H, Tachibana K, Hiranuma S, Takagi D, Kagawa M, Yano A, Okada Y, Morozumi M, Kawakami S. Lens Culinaris Agglutinin-reactive Fraction of Alpha-fetoprotein as a Tumor Marker in a Patient With Nonseminomatous Germ Cell Tumor With Normal Alpha-fetoprotein Level. Clin Genitourin Cancer 2020;18:e309-11. [PMID: 31926880 DOI: 10.1016/j.clgc.2019.12.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Li ZQ, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, Zhang HY, Lv J, Liu YM, Zeng QL, Yan JY, Yu ZJ, Zhang Y. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clin Res Hepatol Gastroenterol. 2017;41:311-318. [PMID: 28237828 DOI: 10.1016/j.clinre.2016.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
8 Elsadek B, Mansour A, Saleem T, Warnecke A, Kratz F. The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. Digestive and Liver Disease 2017;49:213-22. [DOI: 10.1016/j.dld.2016.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
9 Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and 18 F-fluoro-2-deoxyglucose positron emission tomography. Liver Int. 2017;37:592-599. [PMID: 27804192 DOI: 10.1111/liv.13297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Lee JH, Cho CH, Kim SH, Kang JG, Yoo JS, Chang CL, Ko JH, Kim YS. Semi-quantitative measurement of a specific glycoform using a DNA-tagged antibody and lectin affinity chromatography for glyco-biomarker development. Mol Cell Proteomics 2015;14:782-95. [PMID: 25525205 DOI: 10.1074/mcp.O114.043117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chen CT, Liao WY, Hsu CC, Hsueh KC, Yang SF, Teng YH, Yu YL. FUT2 genetic variants as predictors of tumor development with hepatocellular carcinoma. Int J Med Sci 2017;14:885-90. [PMID: 28824326 DOI: 10.7150/ijms.19734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Wang WL, Zheng XL, Zhang ZY, Zhou Y, Hao J, Tang G, Li O, Xiang JX, Wu Z, Wang B. Preoperative γ-glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection. Medicine (Baltimore) 2016;95:e4087. [PMID: 27399101 DOI: 10.1097/MD.0000000000004087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
13 Zhu J, Yu K, de Mello RA. Hepatocellular Carcinoma. In: de Mello RA, Tavares Á, Mountzios G, editors. International Manual of Oncology Practice. Cham: Springer International Publishing; 2015. pp. 327-42. [DOI: 10.1007/978-3-319-21683-6_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Guan W, Gao Z, Huang C, Fang M, Feng H, Chen S, Wang M, Zhou J, Hong S, Gao C. The diagnostic value of serum DSA-TRF in hepatocellular carcinoma. Glycoconj J 2020;37:231-40. [DOI: 10.1007/s10719-019-09906-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Olthoff KM, Goldberg DS. The MoRAL Path Beyond Milan. Annals of Surgery 2016;263:851-2. [DOI: 10.1097/sla.0000000000001679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Hou G, Liu G, Yang Y, Li Y, Yuan S, Zhao L, Wu M, Liu L, Zhou W. Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma. Oncotarget 2016;7:64957-66. [PMID: 27602751 DOI: 10.18632/oncotarget.11778] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
17 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Hou Z, Xie J, Zhang L, Dai G, Chen Y, He L. Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020. Front Oncol 2021;11:702216. [PMID: 34422656 DOI: 10.3389/fonc.2021.702216] [Reference Citation Analysis]
19 Xia Y, Zhang Y, Shen M, Xu H, Li Z, He N. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif 2019;52:e12538. [PMID: 30341783 DOI: 10.1111/cpr.12538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
20 Wang M, Zhu J, Lubman DM, Gao C. Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey. Clin Chem Lab Med 2019;57:407-16. [PMID: 30138110 DOI: 10.1515/cclm-2018-0379] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
21 Huang C, Wu T, Hsu H, Pan K, Lee C, Chong S, Huang S, Lin S, Yu M, Chen S. Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma. JPM 2022;12:518. [DOI: 10.3390/jpm12040518] [Reference Citation Analysis]
22 Takada H, Tsuchiya K, Yasui Y, Nakakuki N, Tamaki N, Suzuki S, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Izumi N. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med 2016;5:3111-20. [PMID: 27748052 DOI: 10.1002/cam4.932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
23 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
24 Zhang J, Ten Dijke P, Wuhrer M, Zhang T. Role of glycosylation in TGF-β signaling and epithelial-to-mesenchymal transition in cancer. Protein Cell 2021;12:89-106. [PMID: 32583064 DOI: 10.1007/s13238-020-00741-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
25 Kimura H, Ohkawa K, Miyazaki M, Sakakibara M, Imanaka K, Tamura T, Sueyoshi H, Takada R, Fukutake N, Uehara H, Ashida R, Ioka T, Nakazawa T, Nakanishi K, Katayama K. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Hepatol Int. 2017;11:105-114. [PMID: 27766479 DOI: 10.1007/s12072-016-9771-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
26 Okagawa Y, Takada K, Arihara Y, Kikuchi S, Osuga T, Nakamura H, Kamihara Y, Hayasaka N, Usami M, Murase K, Miyanishi K, Kobune M, Kato J. Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells. PLoS One. 2016;11:e0168355. [PMID: 27977808 DOI: 10.1371/journal.pone.0168355] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
27 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Núñez KG, Sandow T, Fort D, Patel J, Hibino M, Carmody I, Cohen AJ, Thevenot P. Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4765. [PMID: 34638251 DOI: 10.3390/cancers13194765] [Reference Citation Analysis]
29 Tai BJ, Yao M, Wang L, Qian Q, Shi Y, Yu DD, Lu SL, Yao DF. Down-regulation of glypican-3 gene transcription inhibits hepatoma cell invasion and angiogenesis. Shijie Huaren Xiaohua Zazhi 2014; 22(16): 2221-2228 [DOI: 10.11569/wcjd.v22.i16.2221] [Reference Citation Analysis]
30 Xiang Z, Bai M, Li G, Zou B, Zhong Z, Gao F, Wu C, Huang M, Zhang F. Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation. J Cancer Res Clin Oncol 2019;145:1907-16. [PMID: 31161374 DOI: 10.1007/s00432-019-02943-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer. 2016;8:37-55. [PMID: 27398029 DOI: 10.4137/bic.s34413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
33 Chen S, Zhang Y, Wu X, Zhang C, Li G. Diagnostic Value of lncRNAs as Biomarker in Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol 2018;2018:8410195. [PMID: 30410873 DOI: 10.1155/2018/8410195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
34 Wang Y, Yang X, Yu Y, Xu Z, Sun Y, Liu H, Cheng J, Liu M, Sha B, Li L, Ding N, Li Z, Jin H, Qian Q. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells. J Cancer 2018;9:275-87. [PMID: 29344274 DOI: 10.7150/jca.22176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]